Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors

Intensive Care Medicine

Volumn 29, Issue 9, 2003, Pages 1528-1534

  Barbot, A ^a   Venisse, N ^a   Rayeh, F ^a   Bouquet, S ^a   Debaene, B ^a   Mimoz, O ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

Critically illpatients; Pharmacodynamics; Pharmacokinetics; Safety; Subcutaneous route; Teicoplanin

Indexed keywords

ALBUMIN; CREATININE; HYPERTENSIVE FACTOR; TEICOPLANIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CRITICAL ILLNESS; CROSSOVER PROCEDURE; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; ERYTHEMA; FEMALE; HOSPITAL INFECTION; HUMAN; INFECTION SENSITIVITY; INJECTION PAIN; INTENSIVE CARE UNIT; MALE; RANDOMIZED CONTROLLED TRIAL; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; ALBUMINS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CRITICAL ILLNESS; CROSS INFECTION; CROSS-OVER STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; INJECTIONS, SUBCUTANEOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PROSPECTIVE STUDIES; TEICOPLANIN; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 0141453460     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-003-1859-z     Document Type: Article

References (25)

1. Karchmer AW (2000) Nosocomial bloodstream infections: organisms, risk factors, and implications. Clin Infect Dis 31 Suppl 4:S139-S143
2. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoine MH, Wolff M, Spencer RC, Hemmer M (1995) The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 274:639-644
3. Johnson AP, James D, Livermore DM (1999) Increasing prevalence of methicillin resistance amongst Staphylococcus aureus blood culture isolates. J Antimicrob Chemother 43:160
4. Struelens MJ (1998) The epidemiology of antimicrobial resistance in hospital acquired infections: problems and possible solutions. BMJ 317:652-654
5. Wood MJ (1996) The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 37:209-222
6. Antony KK, Lewis EW, Kenny MT, Dulworth JK, Brackman MB, Kuzma R, Yuh L, Eller MG, Thompson GA (1991) Pharmacokinetics and bioavailability of a new formulation of teicoplanin following intravenous and intramuscular administration to humans. J Pharm Sci 80:605-607
7. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
8. Le Gall JR, Lemeshow S, Saulnier F (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957-2963
9. Brogden RN, Peters DH (1994) Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 47:823-854
10. Lortholary O, Tod M, Rizzo N, Padoin C, Biard O, Casassus P, Guillevin L, Petitjean O (1996) Population pharmacokinetic study of teicoplanin in severely neutropenic patients. Antimicrob Agents Chemother 40:1242-1247
11. Charbonneau P, Harding I, Garaud JJ, Aubertin J, Brunet F, Domart Y (1994) Teicoplanin: a well-tolerated and easily administered alternative to vancomycin for gram-positive infections in intensive care patients. Intensive Care Med 20 Suppl 4:S35-S42
12. Amrein C, Hillaire-Buys D, Guillemain R, Taburet AM, Vulser C, Despeaux E, Singlas E (1992) Teicoplanin can be administered by subcutaneous route. 32e Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim
13. van Dalen R, Vree TB (1990) Pharmacokinetics of antibiotics in critically ill patients. Intensive Care Med16 [Suppl 3]:S235-S238
14. Assandri A, Bernareggi A (1987) Binding of teicoplanin to human serum albumin. Eur J Clin Pharmacol 33:191-195
15. Mimoz O, Binter V, Jacolot A, Edouard AR, Tod M, Petitjean O, Samii K (1998) Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients. Intensive Care Med 24:1047-1051
16. Jacolot A, Incagnoli P, Edouard AR, Tod M, Petitjean O, Samii K, Mimoz O (1999) Pharmacokinetics of cefpirome during the posttraumatic systemic inflammatory response syndrome. Intensive Care Med 25:486-491
17. Mimoz O, Soreda S, Padoin C, Tod M, Petitjean O, Benhamou D (2000) Ceftriaxone pharmacokinetics during iatrogenic hydroxyethyl starch-induced hypoalbuminemia: a model to explore the effects of decreased protein binding capacity on highly-bound drugs. Anesthesiology 93:735-743
18. Mimoz O, Schaeffer V, Incagnoli P, Louchahi K, Edouard A, Petitjean O, Tod M (2001) Amoxicillin-clavulanate pharmacokinetics during post-traumatic hemorrhagic shock. Crit Care Med 29:1350-1355
19. Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antimicrobial dosing in mice and men. Clin Infect Dis 26:1-12
20. Amrein C, Atlani C, Ghirardi L (1997) Teicoplanine par voie sous-cutanée: résultats d'une étude multicentrique rétrospective. 17e Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse, Paris, France
21. Tegeder I, Schmidtko A, Brautigam L, Kirschbaum A, Geisslinger G, Lotsch J (2002) Tissue distribution of imipenem in critically ill patients. Clin Pharmacol Ther 71:325-333
22. Joukhadar C, Frossard M, Mayer BX, Brunner M, Klein N, Siostrzonek P, Eichler HG, Muller M (2001) Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 29:385-391
23. Lesne-Hulin A, Bourget P, Le Bever H, Ainaud P, Carsin H (1997) Therapeutic monitoring of teicoplanin in a severely burned patient. Ann Fr Anesth Reanim 16:374-347
24. Wilson AP (2000) Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 39:167-183
25. Dorffler-Melly J, de Jonge E, Pont AC, Meijers J, Vroom MB, Bullet HR, Levi M (2002) Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 359:849-850